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This study examined whether pathological ﬁndings were present in cochlear vessels for patients with 
diabetes mellitus.  Twenty-six temporal bones from 13 patients with type 1 diabetes mellitus and 40 
temporal bones from 20 patients with type 2 diabetes mellitus were examined.  Type 2 diabetic tempo-
ral bones were divided into 2 groups according to diabetic management (22 temporal bones with insulin 
therapy,  and 18 with oral hypoglycemic drugs).  Age-matched normal control temporal bones were 
also selected.  The vessel wall thickness in the cochlear spiral modiolar artery was measured under a 
light microscope,  and the vessel wall ratio (vessel wall thickness/outer diameter of the vessel×100) 
was calculated.  The vessel wall thickness and vessel wall ratio in type 1 diabetes mellitus were signiﬁ-
cantly greater than in normal controls.  Type 2 diabetic patients with insulin therapy showed signiﬁ-
cantly greater vessel wall thickness and vessel wall ratios than controls.  In type 2 diabetes mellitus,  
the vessel wall thickness and vessel wall ratio were greater in patients treated with insulin therapy than 
in those treated with oral hypoglycemic agents.  Type 2 diabetic patients with insulin therapy showed 
an increased vessel wall thickness and vessel wall ratio compared to patients with type 1 diabetes mel-
litus.  In conclusion,  the cochlea in patients with diabetes mellitus shows circulatory disturbance com-
pared to age-matched normal controls.
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earing loss is a common complication in patients 
with diabetes mellitus,  and hearing thresholds 
in diabetic patients are progressively increased com-
pared with normal subjects [1,  2].  Both type 1 diabe-
tes mellitus (insulin-dependent diabetes mellitus) and 
type 2 diabetes mellitus (non-insulin-dependent diabe-
tes mellitus) appear to be associated with hearing 
impairment [3-5].  As some diabetic patients with 
mild hearing loss may not complain of a hearing disor-
der,  adding routine audiometry to the annual test for 
patients with diabetes mellitus has been recommended 
for physicians by the American Diabetes Association 
[6,  7].  However,  the etiology and nature of the 
hearing loss associated with diabetes mellitus remains 
controversial [8].
　 Diabetes mellitus is strongly associated with accel-
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erated atherogenesis [9].  Increased vessel wall thick-
ness has been reported in human temporal bones with 
diabetes mellitus,  and periodic acid-Schiﬀ (PAS) - 
positive material has been detected in the vascular 
walls of the cochlea in diabetic patients [10-12].  
Although angiopathy and/or neuropathy in the cochlea 
might be considered important in relation to hearing 
disorders in diabetic patients,  the vascular status of 
the inner ear in diabetic patients is not fully under-
stood [13-15].  In addition,  diﬀerences in cochlear 
vessels between type 1 and type 2 diabetes mellitus do 
not appear to have been reported.  The purpose of the 
present human temporal bone study was to clarify 
vascular ﬁndings in cochlear vessels for both type 1 
and type 2 diabetic patients,  and to compare ﬁndings 
between the types of diabetes mellitus.
Materials and Methods
　 Samples. This study examined 26 temporal 
bones from 13 patients with type 1 diabetes mellitus 
(6 men,  7 women; mean age±standard deviation 
(SD),  37.1±13.1 years; range,  18-68 years; mean 
duration of diabetes,  21.1±11.1 years; range,  6-36 
years) and 40 temporal bones from 20 patients with 
type 2 diabetes mellitus.  Temporal bones from 
patients with type 2 diabetes mellitus were divided 
into 2 groups according to the method of diabetes 
management: 11 patients (22 temporal bones) with 
insulin therapy (7 men,  4 women; mean age,  54.6±
7.6 years; range,  44-68 years; mean duration of dia-
betes mellitus,  6.4±5.3 years; range,  0.5-16 years) 
and 9 patients (18 temporal bones) with oral hypogly-
cemic drugs (8 men,  1 woman; mean age,  56.9±8.6 
years; range,  45-68 years; mean duration of diabe-
tes,  6.5±3.1 years; range,  3-10 years).
　 The control group for type 1 diabetes mellitus 
(Control 1) comprised 16 normal temporal bones (7 on 
right side and 9 on left side) from 11 age-matched 
subjects (6 men,  5 women; mean age,  39.6±19.0 
years; range,  12-66 years),  and the control group 
for type 2 diabetes mellitus (Control 2) comprised 11 
normal temporal bones (5 on right side and 6 on left 
side) from 8 age-matched subjects (4 men,  4 women;  
mean age,  55.9±10.6 years; range,  40-67 years).
　 Temporal bones from patients with a history of 
head trauma,  systemic autoimmune disorders,  oto-
toxic drug use,  or otological diseases such as otoscle-
rosis and otitis media were excluded from this study,  
as these factors can aﬀect the cochlea.  Temporal 
bones from patients ＞70 years old were also excluded.  
The characteristics of the patients with diabetes mel-
litus and those of normal controls are shown in Table 
1.
　 Temporal bone samples were obtained from the 
temporal bone collection of the University of 
Minnesota.  All temporal bones had been previously 
removed at autopsy,  ﬁxed in formalin solution,  decal-
ciﬁed,  and embedded in celloidin.  Each temporal bone 
was serially sectioned in the horizontal plane at a 
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Table 1　 Characteristics of the patients with diabetes mellitus and the controls
Type 1 DM Control 1 P value (1) Type 2 DM (Insulin therapy) Type 2 DM (Oral hypoglycemic drug) Control 2 P value (2)
Number of patients 13 11 11 9 8
Age (mean±SD,  year) 37.1±13.1 39.6±19.0 　0.676 54.6±7.6 56.9±8.6 55.9±10.6 0.773
Sex: Male/Female 6/7 6/5 　0.682 7/4 8/1 4/4 0.212
Duration of DM (mean±SD,  year) 21.1±11.1 6.4±5.3 6.5±3.1
Height (mean±SD,  cm) 166.4±12.5 167.3±9.1 　0.961 160.4±5.8 173.8±6.0 167.0±8.4 0.019
Weight (mean±SD,  kg) 57.3±16.2 77.8±30.9 　0.072 79.0±18.8 74.8±10.9 77.4±32.3 0.919
BMI (mean±SD) 20.8±5.2 28.1±11.5 　0.024 31.7±6.1 24.2±2.1 28.7±13.3 0.066
Blood Sugar (mean±SD,  mg/dl) 312±138.5 106.8±21.0 ＜0.001 240.9±109.7 231.7±86.3 109.7±21.9 0.001
BUN (mean±SD,  mg/dl) 50.0±40.1 19.9±10.5 　0.059 34.2±33.2 43.6±18.6 22.9±10.3 0.083
Cre (mean±SD,  mg/dl) 4.5±4.1 1.0±0.8 　0.003 1.5±1.2 4.7±5.3 1.0±0.5 0.023
Number of patients with
　　Hemodialysis 8 (61.5%) 0 ＜0.001 3 (27.3%) 3 (33.3%) 0 0.120
　　Diabetic Retinopathy 9 (69.2%) 0 ＜0.001 2 (18.2%) 0 0 0.227
　　Diabetic Neuropathy 8 (61.5%) 0 ＜0.001 1 ( 9.1%) 0 0 0.564
　　Diabetic Cardiomyopathy 3 (23.1%) 0 　0.047 3 (27.3%) 2 (22.2%) 0 0.185
　　Myocardial Infarction 5 (38.5%) 5 (45.5%) 　0.737 4 (36.4%) 4 (44.4%) 4 (50.0%) 0.843
　　Hypertension 6 (46.2%) 2 (18.2%) 　0.154 3 (27.3%) 3 (33.3%) 2 (25.0%) 0.931
　　Renal transplantation 3 (23.1%) 0 　0.063 0 0 0
BMI,  body mass index; BUN,  blood urea nitrogen; Cre,  serum creatinine.
P value (1): Mann-Whitneyʼs U-test or chi-square test is used to compare between Type 1 DM and Control 1.
P value (2): Kruskal-Wallis test or chi-square test is used to compare between groups (Type 2 DM with insulin,  Type 2 DM with oral drug,  and Control 2).
thickness of 20µm.  Every 10th section was stained 
with hematoxylin and eosin (HE),  mounted on a glass 
slide,  and evaluated under a light microscope.
　 The study was approved by the Institutional 
Review Board (Midwest Center of the National 
Temporal Bone Hearing and Pathology Resource 
Registry; Study number,  0206M26181).
　 Measurement of cochlear vessels. The mid-
modiolar section of the cochlea was selected in each 
temporal bone.  Vessel wall measurements were per-
formed in perpendicular cross-sections of the spiral 
modiolar artery.  The vessel that was most perpen-
dicularly sectioned was chosen in each subject.  Images 
were acquired using a digital camera connected to a 
personal computer.  The calibrated image was obtained 
at a magniﬁcation of×600.  Vessel walls were mea-
sured using Image-Pro Plus version 3.0 image analysis 
software (Media Cybernetics,  Silver Springs,  MD,  
USA) and calculated with reference to the methods 
described by Robison [16].
　 The vessel wall area (VWA) and vessel wall length 
(VWL) per vessel cross-section were determined using 
the following formulae:
　 VWA＝T－Lu
　 VWL＝ (outer length of lines delimiting VWA＋
inner length of lines delimiting VWA)/2,  where T is 
the total cross-sectional area of each vessel and Lu is 
the luminal area.  Vessel wall thickness in each vessel 
is expressed as VWA/VWL.
　 The vessel wall ratio was determined with the fol-
lowing formula:
　 Vessel wall ratio (ｵ)＝vessel wall thickness/outer 
diameter of the vessel×100
　 Statistical analysis. Results are presented as 
means±standard deviation (SD).  Statistical evalua-
tions were performed using the Kruskal-Wallis test,  
the Tukey-Kramer test,  and the chi-square test for 
comparing data among 3 or more groups.  Mann-
Whitneyʼs U test was used for comparison between 2 
groups.  A correlation analysis was performed by using 
Spearmanʼs correlation coeﬃcient by rank test.  Sig-
niﬁcant diﬀerences were established at a level of p＜
0.05.
Results
　 Vessel wall thickness. Vessel walls of the 
spiral modiolar artery were thick in patients with 
diabetes mellitus (Fig.  1).  Vessel wall thicknesses of 
the spiral modiolar artery are shown in Fig.  2.  The 
mean vessel wall thickness was 6.02±1.70µm in type 
1 diabetes mellitus,  3.55±0.72µm in Control 1,  
6.97±1.88µm in type 2 diabetes mellitus with insulin 
therapy,  5.08±1.41µm in type 2 diabetes mellitus 
with oral hypoglycemic agents,  and 3.77±0.81µm in 
Control 2.  A statistically signiﬁcant diﬀerence was 
observed between groups (p＜0.001,  Kruskal-Wallis 
test).  The vessel wall thickness was signiﬁcantly 
higher in type 1 diabetes mellitus than in normal 
Control 1 (p＜0.001,  Tukey-Kramer test).  Type 2 
diabetes mellitus with insulin therapy also showed a 
signiﬁcantly greater vessel wall thickness than 
Control 2 (p＜0.001,  Tukey-Kramer test).  No sig-
niﬁcant diﬀerence in vessel wall thickness was seen 
between Control 1 and Control 2.  The vessel wall 
thickness in type 2 diabetes mellitus with insulin 
therapy tended to be higher,  although not signiﬁ-
cantly,  than in type 1 diabetes mellitus or in type 2 
diabetes mellitus with oral hypoglycemic agents.
　 In some normal cases,  the same individual contrib-
uted both ears to the sample population.  Vessel wall 
thicknesses in right temporal bones both in patients 
with diabetes mellitus and in controls are shown in 
Fig.  3.  The mean vessel wall thickness was 6.01±
1.43µm in type 1 diabetes mellitus,  3.42±0.82µm in 
Control 1,  6.21±1.78µm in type 2 diabetes mellitus 
with insulin therapy,  4.77±1.59µm in type 2 diabetes 
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Fig. 1　 Vessels in the midmodiolus of the left cochlea in type 2 
diabetes mellitus with insulin therapy (65 years old,  male).  The 
vessel wall thickness of the spiral modiolar artery (arrow) is increased.
mellitus with oral hypoglycemic agents,  and 3.37±
0.96µm in Control 2.  A statistically signiﬁcant diﬀer-
ence was observed between groups (p＜0.001,  
Kruskal-Wallis test).  The vessel wall thickness in the 
right temporal bone was signiﬁcantly higher in type 1 
diabetes mellitus than in normal Control 1 (p＜0.01,  
Tukey-Kramer test).  Type 2 diabetes mellitus with 
insulin therapy also showed a signiﬁcantly greater 
vessel wall thickness than Control 2 (p＜0.05,  
Tukey-Kramer test).
　 Vessel wall thicknesses in the left temporal bones 
both in patients with diabetes mellitus and in controls 
are shown in Fig.  4.  The mean vessel wall thickness 
was 6.02±1.98µm in type 1 diabetes mellitus,  3.65
±0.66µm in Control 1,  7.80±1.70µm in type 2 dia-
betes mellitus with insulin therapy,  5.39±1.24µm in 
type 2 diabetes mellitus with oral hypoglycemic 
agents,  and 4.10±0.54µm in Control 2.  A statisti-
cally signiﬁcant diﬀerence was observed between 
groups (p＜0.001,  Kruskal-Wallis test).  The vessel 
wall thickness in the left temporal bone was signiﬁ-
cantly higher in type 1 diabetes mellitus than in nor-
mal Control 1 (p＜0.05,  Tukey-Kramer test).  Type 2 
diabetes mellitus with insulin therapy also showed a 
signiﬁcantly greater vessel wall thickness than 
Control 2 (p＜0.01,  Tukey-Kramer test).
　 Vessel wall ratio. The vessel wall ratios of the 
spiral modiolar artery are shown in Fig.  5.  The mean 
vessel wall ratio was 9.37±2.50ｵ in type 1 diabetes 
mellitus,  5.80±1.40ｵ in Control 1,  12.5±3.74ｵ in 
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Fig. 3　 Vessel wall thickness (means±SD) in the spiral modiolar 
artery in right temporal bones.  (n.s.,  not signiﬁcant; Tukey-Kramer 
test)
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Fig. 4　 Vessel wall thickness (means±SD) in the spiral modiolar 
artery in left temporal bones.  (n.s.,  not signiﬁcant; Tukey-Kramer 
test)
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Fig. 2　 Vessel wall thickness (means±SD) in the spiral modiolar 
artery in temporal bones,  combining those on the right and left 
sides.  (n.s.,  not signiﬁcant; Tukey-Kramer test)
type 2 diabetes mellitus with insulin therapy,  8.56±
2.38ｵ in type 2 diabetes mellitus with oral hypogly-
cemic agents,  and 6.37±1.59ｵ in Control 2.  A sta-
tistically signiﬁcant diﬀerence was observed between 
groups (p＜0.001,  Kruskal-Wallis test).  The vessel 
wall ratio was signiﬁcantly greater in type 1 diabetes 
mellitus than in normal Control 1 (p＜0.001,  Tukey-
Kramer test).  The vessel wall ratio was signiﬁcantly 
greater in type 2 diabetes mellitus with insulin therapy 
than in type 2 diabetes mellitus with oral hypoglyce-
mic agents (p＜0.05,  Tukey-Kramer test) or in normal 
Control 2 (p＜0.001,  Tukey-Kramer test).  The vessel 
wall ratio in type 2 diabetes mellitus with oral hypo-
glycemic agents was greater than that in normal 
Control 2,  but the diﬀerence did not reach statistical 
signiﬁcance.  The vessel wall ratio was higher in type 
2 diabetes mellitus with insulin therapy than in type 1 
diabetes mellitus.  No signiﬁcant diﬀerence in vessel 
wall ratio was seen between Control 1 and Control 2.
　 The vessel wall ratios in right temporal bones both 
in patients with diabetes mellitus and in controls are 
shown in Fig.  6.  The mean vessel wall ratio was 8.38
±1.81ｵ in type 1 diabetes mellitus,  5.91±2.08ｵ in 
Control 1,  11.75±3.26ｵ in type 2 diabetes mellitus 
with insulin therapy,  7.85±2.78ｵ in type 2 diabetes 
mellitus with oral hypoglycemic agents,  and 6.26±
2.41ｵ in Control 2.  A statistically signiﬁcant diﬀer-
ence was observed between groups (p＜0.001,  
Kruskal-Wallis test).  The vessel wall ratio in the 
right temporal bone was higher in type 1 diabetes 
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Fig. 5　 Vessel wall ratio (means±SD) in the spiral modiolar 
artery in temporal bones,  combining those on the right and left 
sides.  (n.s.,  not signiﬁcant; Tukey-Kramer test)
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Fig. 6　 Vessel wall ratio (means±SD) in the spiral modiolar 
artery in right temporal bones.  (n.s.,  not signiﬁcant; Tukey-Kramer 
test)
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Fig. 7　 Vessel wall ratio (means±SD) in the spiral modiolar 
artery in left temporal bones.  (n.s.,  not signiﬁcant; Tukey-Kramer 
test)
mellitus than in normal Control 1.  Type 2 diabetes 
mellitus with insulin therapy showed a signiﬁcantly 
greater vessel wall ratio than type 2 diabetes mellitus 
with oral hypoglycemic agents (p＜0.05,  Tukey-
Kramer test) or Control 2 (p＜0.01,  Tukey-Kramer 
test).
　 Vessel wall ratios in left temporal bones both in 
patients with diabetes mellitus and in controls are 
shown in Fig.  7.  The mean vessel wall ratio was 
10.36±2.76ｵ in type 1 diabetes mellitus,  5.71±
0.66ｵ in Control 1,  13.31±4.24ｵ in type 2 diabe-
tes mellitus with insulin therapy,  9.27±1.81ｵ in 
type 2 diabetes mellitus with oral hypoglycemic 
agents,  and 6.47±0.65ｵ in Control 2.  A statisti-
cally signiﬁcant diﬀerence was observed between 
groups (p＜0.001,  Kruskal-Wallis test).  The vessel 
wall ratio in the left temporal bone was signiﬁcantly 
higher in type 1 diabetes mellitus than in normal 
Control 1 (p＜0.001,  Tukey-Kramer test).  Type 2 
diabetes mellitus with insulin therapy showed signiﬁ-
cantly greater vessel wall thickness than Control 2 (p
＜0.01,  Tukey-Kramer test).
　 Relation with systemic indicators. Body 
mass index (BMI) was signiﬁcantly correlated with 
vessel wall ratio in type 2 diabetes mellitus with 
insulin therapy (p＜0.05,  Spearmanʼs correlation coef-
ﬁcient by rank test) and in type 2 diabetes mellitus 
with oral hypoglycemic agents (p＜0.05,  Spearmanʼs 
correlation coeﬃcient by rank test).  The vessel wall 
thicknesses in diabetes cases and the vessel wall ratio 
in type 1 diabetes mellitus tended to correlate with 
body mass index.  Blood sugar,  blood urea nitrogen,  
and serum creatinine were not signiﬁcantly correlated 
with the vessel wall thickness or vessel wall ratio in 
diabetes cases.
　 The vessel wall thickness and vessel wall ratios in 
diabetic patients with or without related complica-
tions (hemodialysis,  diabetic retinopathy,  diabetic 
neuropathy,  diabetic cardiomyopathy,  myocardial 
infarction,  and hypertension) are shown in Table 2.  In 
type 2 diabetes mellitus with insulin therapy,  the ves-
sel wall thickness and vessel wall ratio were greater 
in patients with related complications than in those 
without complications,  especially in diabetic retinopa-
thy (p＜0.05,  Mann-Whitneyʼs U test).
　 Right side and left side correlation. A sta-
tistically signiﬁcant correlation was detected between 
the right and left temporal bones both in the vessel 
wall thickness and vessel wall ratio in type 1 diabetes 
mellitus (Vessel wall thickness,  p＜0.05; vessel wall 
ratio,  p＜0.01; Spearmanʼs correlation coeﬃcient by 
rank test).  Right and left temporal bones tended to 
correlate both in the vessel wall thickness and the 
vessel wall ratio in type 2 diabetes mellitus.  Control 
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Table 2　 Vessel wall thickness and vessel wall ratio in diabetic patients with or without related complications
Type 1 DM Type 2 DM (Insulin) Type 2 DM (Oral)
Thickness (µm) Ratio (%) Thickness (µm) Ratio (%) Thickness (µm) Ratio (%)
Hemodialysis
＋ 6.10±1.88 9.61±2.56 7.24±2.64 12.67±3.45 5.68±1.85 7.37±1.03
－ 5.88±1.44 8.98±2.47 6.86±1.59 12.42±3.97 4.72±1.02 9.28±2.70
Diabetic retinopathy
＋ 5.75±1.52 8.75±1.65 7.83±0.42 15.38±2.73＊＊ － －
－ 6.60±2.02 10.77±3.53 6.77±2.04 11.82±3.68 5.08±1.41 8.56±2.38
Diabetic neuropathy
＋ 5.90±1.55 8.98±1.60 7.68±0.48 15.79±4.62 － －
－ 6.20±1.97 10.00±3.52 6.89±1.97 12.15±3.61 5.08±1.41 8.56±2.38
Diabetic cardiomyopathy
＋ 5.37±1.16 7.86±1.16 8.03±2.33 13.73±3.45 5.20±1.11 8.31±2.39
－ 6.21±1.81 9.82±2.63 6.54±1.57 12.00±3.85 5.04±1.54 8.65±2.47
Myocardial infarction
＋ 5.65±1.21 8.41±1.42 7.94±1.98 14.25±3.53 4.76±1.40 7.94±2.54
－ 6.25±1.94 9.97±2.86 6.37±1.61 11.42±3.58 5.33±1.45 9.05±2.27
Hypertension
＋ 5.99±1.52 9.11±1.56 8.84±3.20 16.19±3.85 4.88±1.36 9.03±1.49
－ 6.04±1.89 9.59±3.13 6.77±1.72 12.11±3.62 5.15±1.48 8.41±2.65
Values are presented as mean±SD.
＊＊,  p＜0.05,  Mann-Whitneyʼs U test.
1 showed signiﬁcant correlation between right and left 
temporal bones in the vessel wall thickness (p＜0.001,  
Spearmanʼs correlation coeﬃcient by rank test) and 
vessel wall ratio (p＜0.001,  Spearmanʼs correlation 
coeﬃcient by rank test).  Because only 3 cases con-
tributed both ears in Control 2,  statistical analysis 
was not performed.
Discussion
　 A relationship between hearing loss and diabetes 
mellitus has been suggested for several decades.  A 
recent study examined 5,140 participants to determine 
relative risk for sensorineural hearing loss in a com-
munity-based random sample of patients who reported 
a history of diabetes mellitus,  and concluded that 
patients with diabetes mellitus are at increased risk 
for hearing loss [17].  Another large population-based 
study recruited 3,572 participants,  including 344 type 
2 diabetic patients,  and showed a modest association 
between type 2 diabetes mellitus and hearing loss [3].  
Agrawal et al.  have reported that a history of diabetes 
is associated with signiﬁcantly increased odds of hear-
ing loss in a national cross-sectional survey (adjusted 
odds ratios,  2.0; 95ｵ conﬁdence interval,  1.2-3.2),  
with diabetic patients showing signiﬁcantly poorer 
hearing levels at 0.5,  1,  3,  4,  6,  and 8 kHz in audi-
ometry compared with those without diabetes [18].  
These studies have clearly demonstrated diabetes mel-
litus to be one of the risk factors for sensorineural 
hearing loss.
　 The mechanism of sensorineural hearing loss 
induced by diabetes mellitus remains a source of 
debate.  Multiple factors,  including nonenzymatic 
glycation related to the hyperactivity of free oxygen 
radicals,  might result in functional impairment of 
outer hair cells of the cochlea [4].  The cochlea is 
supplied by the spiral modiolar artery and the 
cochlear branch of the vestibulo-cochlear artery,  
which are terminal branches of the inner ear artery 
[19].  Circulatory disturbance induced by microvascu-
lar problems has also been suggested as one of the 
principal factors underlying sensorineural hearing loss 
in patients with diabetes mellitus [11,  20-22].  The 
present study clearly shows that the cochlear vessel 
wall is signiﬁcantly thicker in both type 1 and type 2 
diabetic patients when compared with age-matched 
normal controls.  In addition,  although there was no 
signiﬁcant diﬀerence in vessel walls between young 
control subjects and elderly control subjects,  patients 
who managed type 2 diabetes by using insulin therapy 
displayed thicker vessel walls than other diabetic 
patients.  Our ﬁndings revealed that the cochlear 
microcirculation in patients with diabetes mellitus is 
aﬀected,  especially in type 2 diabetic patients receiv-
ing insulin therapy.
　 Carotid intima-media thickness as measured by 
ultrasound examination is a useful non-invasive assess-
ment of cardiovascular disease in diabetic patients 
[23].  Recent studies have shown that carotid intima-
media thickness is associated with the extent of ath-
erosclerosis and end-organ damage,  and that increased 
carotid intima-media thickness is related to hearing 
disorder in general adult population samples [24,  25].  
Thickened cochlear vessel walls in the diabetic 
patients observed in this study might be related to 
cochlear dysfunction,  including sensorineural hearing 
loss,  in patients with diabetes mellitus.
　 Multiple factors might aﬀect vascular disorders in 
patients with diabetes mellitus.  Endothelial dysfunc-
tion is one of the principal factors closely associated 
with the development of atherosclerosis in both type 1 
and type 2 diabetes mellitus [26,  27].  Abnormal 
production of various mediators in the endothelium,  
including nitric oxide,  prostanoids,  endothelin,  tis-
sue-type plasminogen activator (t-PA),  plasminogen 
activator inhibitor-1 (PAI-1),  adhesion molecules,  and 
inﬂammatory cytokines,  results in endothelial dys-
function per se and atherosclerosis [28].  Type 2 dia-
betes mellitus is initially characterized by insulin 
resistance,  and the progression of insulin resistance 
parallels the development of endothelial dysfunction 
and atherosclerosis [29].  Our ﬁndings show that 
cochlear vessel wall thickness in type 2 diabetic 
patients with insulin therapy is greater than that in 
type 2 diabetic patients with oral hypoglycemic agents.  
Patients managed by insulin might be at a more severe 
stage of type 2 diabetes mellitus,  and diﬀerences in 
vessel wall thickness between those treated with 
insulin and those with oral hypoglycemic agents 
observed in this study might reﬂect the progression of 
insulin resistance.
　 Conversely,  endothelial impairment does not fully 
explain the development of angiopathy in patients with 
type 1 diabetes mellitus,  and genetic factors such as 
angiotensin II type 1 receptor gene polymorphism 
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inﬂuence vascular disorders in patients with type 1 
diabetes mellitus [29,  30].  Our ﬁndings show that 
cochlear vessel wall thickness is smaller in type 1 
diabetic patients than in type 2 diabetic patients with 
insulin therapy.  Factors other than endothelial dys-
function may therefore need to be present for athero-
sclerosis to develop in type 1 diabetes mellitus.  
Kanters et al.  have examined hyperlipidemic patients 
with type 1 or type 2 diabetes mellitus,  and reported 
that the thickness of the carotid intima is greater in 
those with type 2 diabetes than in those with type 1 
[31].  Although they did not divide type 2 diabetic 
patients according to management,  our results do not 
contradict their ﬁndings.
　 Due to the limited number of subjects with avail-
able audiograms,  the relationship between hearing 
level and vessel wall thickness in the cochlea was 
unclear in this study.  A positive correlation between 
the severity of hearing loss and the progression of 
diabetes mellitus has been reported,  but audiological 
ﬁndings in various conditions of diabetic patients 
remain controversial [2,  32-34].  As signiﬁcant dif-
ferences were observed in this study in terms of vessel 
wall thickness in the cochlea between subtypes of 
diabetes mellitus,  further studies are needed to clar-
ify the pathophysiology of the inner ear in patients 
with diabetes mellitus.
　 Conclusion. The thickness of the cochlear 
vessel wall in diabetic patients was increased,  espe-
cially in patients with type 2 diabetes managed by 
insulin therapy.  Our ﬁndings suggest that cochlear 
microcirculation might be aﬀected in patients with 
diabetes mellitus.  Administration of vasodilators,  
corticosteroids,  vitamin B12,  and hyperbaric oxygen 
therapy results in a better recovery rate from idio-
pathic sudden deafness in patients with diabetes mel-
litus than in those without diabetes mellitus [21].  The 
vessel wall ﬁndings in this study may indicate that the 
cochlea is under an ischemic state in patients with 
diabetes mellitus,  and that pharmacotherapies known 
to improve microcirculation in the cochlea might be 
worth considering for the management of inner ear 
disturbances,  including tinnitus and sensorineural 
hearing loss.
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